Pharmacological effects of formulation vehicles : implications for cancer chemotherapy.
about
Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancerTargeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients?Evolving Evidence of the Efficacy and Safety of nab-Paclitaxel in the Treatment of Cancers with Squamous HistologiesTaxanes in the elderly patient with metastatic breast cancerAlbumin-bound paclitaxel in solid tumors: clinical development and future directionsClinical Translation of Nanomedicine.Development and characterization of stabilized double loaded mPEG-PDLLA micelles for simultaneous delivery of paclitaxel and docetaxel.Data Mining as a Guide for the Construction of Cross-Linked Nanoparticles with Low Immunotoxicity via Control of Polymer Chemistry and Supramolecular Assembly.Co-administration with cell penetrating peptide enhances the oral bioavailability of docetaxel-loaded nanoparticles.nab-paclitaxel for the management of patients with advanced non-small-cell lung cancer.Multi-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs.Phase II Study of Modified Carboplatin Plus Weekly Nab-Paclitaxel in Elderly Patients with Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301Differential pharmacodynamic effects of paclitaxel formulations in an intracranial rat brain tumor model.Organic effects of associating paclitaxel with a lipid-based nanoparticle system on a nonhuman primate, Cebus apella.Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.Targeted delivery of albumin bound paclitaxel in the treatment of advanced breast cancer.Synthesis, characterization, and in vivo efficacy evaluation of PGG-docetaxel conjugate for potential cancer chemotherapyPlasma, tumor and tissue pharmacokinetics of Docetaxel delivered via nanoparticles of different sizes and shapes in mice bearing SKOV-3 human ovarian carcinoma xenograft.Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma.Determination of docetaxel in rat plasma and its application in the comparative pharmacokinetics of Taxotere and SID530, a novel docetaxel formulation with hydroxypropyl-β-cyclodextrin.Taxane pathway.Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer.Novel formulations of taxanes: a review. Old wine in a new bottle?Adverse drug reaction profile of nanoparticle versus conventional formulation of paclitaxel: An observational studySafety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer.Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval.Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.nab-Paclitaxel dose and schedule in breast cancerEGFR-mediated intracellular delivery of Pc 4 nanoformulation for targeted photodynamic therapy of cancer: in vitro studies.Functionalized graphene oxide-based thermosensitive hydrogel for near-infrared chemo-photothermal therapy on tumor.Weekly nab-Paclitaxel in Metastatic Breast Cancer - Summary and Results of an Expert Panel Discussion.Enhanced oral bioavailability of docetaxel by lecithin nanoparticles: preparation, in vitro, and in vivo evaluationPharmacokinetic study of 3-in-1 poly(ethylene glycol)-block-poly(D, L-lactic acid) micelles carrying paclitaxel, 17-allylamino-17-demethoxygeldanamycin, and rapamycinAntitumor activity of Triolimus: a novel multidrug-loaded micelle containing Paclitaxel, Rapamycin, and 17-AAG.Multi-drug loaded micelles delivering chemotherapy and targeted therapies directed against HSP90 and the PI3K/AKT/mTOR pathway in prostate cancerTaxanes for the treatment of metastatic breast cancer.Hydrophilically modified self-assembling α-tocopherol derivative as niosomal nanocarrier for improving clarithromycin oral bioavailability.A toxic organic solvent-free technology for the preparation of PEGylated paclitaxel nanosuspension based on human serum albumin for effective cancer therapy.Stable isotope method to measure drug release from nanomedicines.Intravenous Single-Dose Toxicity of Redaporfin-Based Photodynamic Therapy in Rodents.
P2860
Q24657308-5DA0F204-EEDB-4534-A250-8A91DE4CEDBAQ26745420-7CDA1B19-C5E8-4DC7-9038-C4D650A526B3Q26766254-AA72B19A-E8BC-4DB2-B203-9F4DFCF23F25Q26785458-9212955A-4CD5-45B5-AA3C-61D0D94DC621Q26798674-F9CB657F-1BE7-4A08-B6FB-D38207816E0BQ30355939-D9B5ABA2-D3C7-4CFF-A0FE-B057F92D7B1AQ30618973-3ACD3D42-822F-4A1E-9C8A-AF822573CBC8Q30958719-AF1C0DB2-FA66-4AC3-BAD9-E68DA3D2E5C3Q31154684-52C93D37-6ED4-40DE-9F55-8FBD8F835A2DQ33412928-28E92D29-07EF-42E5-947E-2AAF6E3B590EQ33437949-39CBC3AD-E3CA-45EB-888B-4B1998EC03B8Q33442004-0F44FD80-CB4B-4B3B-A839-AA3AD1574B10Q33613579-9B0D524C-66B0-4FAD-AF29-A5E0C77FA8D5Q33719235-41596133-1FBA-4827-B9A4-43A3937081C0Q33738990-18189A95-5CA2-4DF5-9AD1-C66BCFA387C3Q33916040-4378E729-C9AE-4CBF-A7D2-66CE17A8C5F2Q34159161-B78BB3FD-146D-4484-9B26-419029BEF139Q34316088-B7CA2088-BE5F-437A-B487-FAF9F63A7F00Q34343995-FECF94FC-53D2-4E14-8BD0-67CD631F6529Q34353491-4630F8EA-DC09-46CF-AAAE-350E2B819FDCQ34390370-6E3565A0-95F8-4508-9FAF-EAC228F8FA65Q34458581-A58755BA-B400-4BDE-AEF3-47829E4ABC3BQ34563540-9B126B47-5589-448C-B6D7-9579EEBE8FB4Q34843961-263AC79E-28D4-4844-A3CC-5A7EB6BA0B6FQ34965672-BBD1BEAB-9184-4CDC-9264-3560EE432425Q35128729-9DA2A82B-1FA1-4634-ADEC-A8E88BF57036Q35507680-35DE37FB-2B43-4A96-A8B2-D484B4C1B212Q35734193-B8355D67-CC3C-4E34-84E5-E9648861BAC3Q35851952-026F0079-9126-4093-BFE8-AA426965F6B1Q35892379-0D15593C-2171-4D49-BD3D-ECE631ABFFD8Q36036125-9D4E439E-AEFC-4CFB-A9AF-00949A090FD9Q36119605-74ABE92C-0611-4E2F-B4F9-86A334F703F9Q36174463-F601AE65-2730-4D32-B157-5C9C4401FF89Q36312850-F5EE1D85-9ECD-4E29-922D-5C8C0703DAAEQ36325610-F6D6A679-0C3B-4582-A6E5-D66C9F72B356Q36364762-7C28668E-21AD-4E5C-90CD-AA1C37FA36F8Q36379940-4A92382A-B8FC-41E7-B067-045A81110F4FQ36391010-22F58AD2-0927-48E7-9932-50E5A5FA9AAEQ36395612-5A676465-3AB3-460A-A044-38BBDE08852BQ36404170-3DD73092-A2B4-41F1-BA0D-002B9EE1E6B4
P2860
Pharmacological effects of formulation vehicles : implications for cancer chemotherapy.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
name
Pharmacological effects of formulation vehicles : implications for cancer chemotherapy.
@ast
Pharmacological effects of formulation vehicles : implications for cancer chemotherapy.
@en
type
label
Pharmacological effects of formulation vehicles : implications for cancer chemotherapy.
@ast
Pharmacological effects of formulation vehicles : implications for cancer chemotherapy.
@en
prefLabel
Pharmacological effects of formulation vehicles : implications for cancer chemotherapy.
@ast
Pharmacological effects of formulation vehicles : implications for cancer chemotherapy.
@en
P2093
P1476
Pharmacological effects of formulation vehicles : implications for cancer chemotherapy.
@en
P2093
Albert J ten Tije
Jaap Verweij
Walter J Loos
P304
P356
10.2165/00003088-200342070-00005
P577
2003-01-01T00:00:00Z
P5875
P6179
1026363657